The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti CD32 moiety linked to a TLR9 ligand and a first peptidic alpha helix and b. a gastrin 17 peptide immunogen linked to a second peptidic alpha helix coiled to the first alpha helix which peptide immunogen is any of (i) human gastrin 17 comprising the amino acid sequence of SEQ ID 1 or a fragment thereof comprising the amino acid sequence of SEQ ID 2 or at least the 4 N terminal amino acids of SEQ ID 2 (ii) an analog of (i) preferably of rhesus monkey or murine origin and/or (iii) a functionally active variant of any of (i) or (ii) with one two three or four point mutations in the amino acid sequence of SEQ ID 2. The invention further provides a kit for producing such immunogenic composition a vaccine comprising such immunogenic composition and its medical use such as for treating gastrin dependent diseases.
